Show simple item record

dc.contributor.authorBenjamin, J.
dc.contributor.authorMoore, Brioni
dc.contributor.authorLee, S.
dc.contributor.authorSenn, M.
dc.contributor.authorGriffin, S.
dc.contributor.authorLautu, D.
dc.contributor.authorSalman, S.
dc.contributor.authorSiba, P.
dc.contributor.authorMueller, I.
dc.contributor.authorDavis, T.
dc.date.accessioned2017-01-30T15:04:58Z
dc.date.available2017-01-30T15:04:58Z
dc.date.created2016-11-03T19:30:24Z
dc.date.issued2012
dc.identifier.citationBenjamin, J. and Moore, B. and Lee, S. and Senn, M. and Griffin, S. and Lautu, D. and Salman, S. et al. 2012. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: A tolerability, safety, and preliminary efficacy study. Antimicrobial Agents and Chemotherapy. 56 (5): pp. 2465-2471.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/43122
dc.identifier.doi10.1128/AAC.06248-11
dc.description.abstract

Artemisinin-naphthoquine (ART-NQ) is a fixed-dose coformulated antimalarial therapy recommended as a single-dose treatment and marketed in Papua New Guinea among other tropical countries. We conducted a tolerability, safety, and efficacy study of ART-NQ for Papua New Guinean children aged 5 to 12 years with uncomplicated malaria, comparing single-dose ART-NQ (15 and 6 mg/kg of body weight) given with water (group 1; n = 15), single-dose ART-NQ (22 and 9 mg/kg) given with milk (group 2; n = 17), or two daily doses of 22 and 9 mg/kg given with water (group 3; n = 16). Of the 48 children (45 with Plasmodium falciparum malaria, 2 with Plasmodium vivax malaria, and 1 with mixed-species malaria), 2 in group 2 did not attend all follow-up assessments. All regimens were well tolerated, with no serious adverse events. There were no clinically significant changes in pulse, blood pressure, rate-corrected electrocardiographic QT, routine biochemistry/hematology, or hearing after treatment. Fever clearance was prompt. Mean 50% parasite clearance times were 4, 4, and 5 h for groups 1, 2, and 3, respectively. One group 1 patient had PCR-confirmed P. falciparum recrudescence at day 23; four had PCR-confirmed P. falciparum reinfections on day 28 or 42; and three had P. vivax infections detected on day 42. The only recurrent parasitemia in groups 2 and 3 occurred in a group 2 child who developed a P. vivax infection on day 42. Day 14 gametocyte positivity levels were 20%, 27%, and 9% in groups 1, 2, and 3, respectively. The lower single ART-NQ dose was associated with relatively frequent recurrence of parasitemia, but the prolonged gametocytemia in all three groups has implications for the transmission of malaria. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

dc.publisherAmerican Society for Microbiology
dc.titleArtemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: A tolerability, safety, and preliminary efficacy study
dc.typeJournal Article
dcterms.source.volume56
dcterms.source.number5
dcterms.source.startPage2465
dcterms.source.endPage2471
dcterms.source.issn0066-4804
dcterms.source.titleAntimicrobial Agents and Chemotherapy
curtin.departmentSchool of Pharmacy
curtin.accessStatusOpen access via publisher


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record